Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
5.074
Zitationen
17
Autoren
2006
Jahr
Abstract
Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoregional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head and neck. (ClinicalTrials.gov number, NCT00004227.)
Ähnliche Arbeiten
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
1993 · 15.625 Zit.
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
2010 · 6.404 Zit.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
2016 · 4.940 Zit.
Head and neck squamous cell carcinoma
2020 · 3.822 Zit.
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 · 3.673 Zit.
Autoren
Institutionen
- University of Alabama at Birmingham(US)
- University of Alabama at Birmingham Hospital(US)
- University of Wisconsin–Madison(US)
- Hebron University(PS)
- Merck (Germany)(DE)
- The University of Texas MD Anderson Cancer Center(US)
- University of Virginia(US)
- University of the Witwatersrand(ZA)
- University of Colorado Anschutz Medical Campus(US)
- Gdańsk Medical University(PL)